Actym Closes $59.5 Million Series A with New $25.5 Million Extension
Actym Therapeutics adds $25.5 million to close its Series A with $59.5 million total New investor GKCC LLC joins syndicate Capital will propel lead program ACTM-838 into first-in-human oncology trial and further advance proprietary STACT platform BERKELEY, CA — October 18, 2023 Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today […]
Article Date
October 18, 2023
This article is featured on another website.
Go to article
May 26, 2026
Closing the Cross-Border Gap for Global Trials
Closing the Cross-Border Gap: Why Modern Global CROs Must Link Regulatory Strategy to Multi-Region Execution.…
May 26, 2026
Closing the Cross-Border Gap for Global Trials
Closing the Cross-Border Gap: Why Modern Global CROs Must Link Regulatory Strategy to Multi-Region Execution.…
July 10, 2026
Sarcoma Clinical Trials – Cell Therapy’s Solid-Tumor Breakthrough, and What It Means for a Rare Cancer
A Turning Point for Cell Therapy in Solid Tumors, and for Sarcoma For most of…
July 10, 2026
Sarcoma Clinical Trials – Cell Therapy’s Solid-Tumor Breakthrough, and What It Means for a Rare Cancer
A Turning Point for Cell Therapy in Solid Tumors, and for Sarcoma For most of…